29
total announcements
544122.BO · 15 min delayed
Entero Healthcare Solutions Ltd
Entero Healthcare Solutions Ltd has submitted a certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018, confirming that no dematerialisation/rematerialisation of securities occurred from July 1, 2026 to September 30, 2026.
Entero Healthcare Solutions Ltd
Entero Healthcare Solutions Ltd has informed the stock exchanges about the allotment of 43,155 equity shares to eligible employees upon exercise of stock options under the Entero Employee Stock Option Plan 2023.
Entero Healthcare Solutions Ltd
Entero Healthcare Solutions Ltd has closed its trading window for insiders from October 1, 2026, until 48 hours after the announcement of its unaudited Q2 FY2026-27 results, which will be considered by the board on an unspecified date.
Entero Healthcare Solutions Ltd
Entero Healthcare Solutions Ltd has announced the schedule of analyst/institutional investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015. The meetings will be held on September 29, 2026, and will be based on publicly available information.
Entero Healthcare Solutions Ltd
Entero Healthcare Solutions Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Surbhi Singh - Prasid Uno Family Trust.
Entero Healthcare Solutions Ltd
Entero Healthcare Solutions Ltd has informed the BSE about a monetary penalty levied by the GST Authority on its subsidiary ACE Cardiopathy Solutions Private Limited for non-generation of E-Invoice, amounting to Rs. 12,91,728, which has been paid under protest.
Entero Healthcare Solutions Ltd
Entero Healthcare Solutions Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Surbhi Singh Prasid Uno Family Trust.
Entero Healthcare Solutions Ltd
Entero Healthcare Solutions Ltd has announced the schedule of analyst/institutional investor meetings under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meetings will be held on September 2, 2026, at Elara Capital in Mumbai, and will be based on publicly available information.
Entero Healthcare Solutions Ltd
Entero Healthcare Solutions Ltd has announced the completion of tenure of Mr. Rajesh Shashikant Dalal as Non-Executive Independent Director, effective August 24, 2026.
Entero Healthcare Solutions Ltd
Entero Healthcare Solutions Ltd held its 8th Annual General Meeting (AGM) on August 19, 2026, through video conferencing. The meeting was attended by the Chairman of the Board, Mr. Sujesh Vasudevan, and the Group General Counsel & Company Secretary, Ms. Sanu Kapoor. The voting results along with the Scrutinizer's Report are available on the company's website and on the website of the National Securities Depository Limited.
Entero Healthcare Solutions Ltd
Entero Healthcare Solutions Ltd held its 8th Annual General Meeting on August 19, 2026, through video conferencing, where the company provided remote e-voting facility to its members. The meeting was chaired by Mr. Sujesh Vasudevan, and the proceedings were recorded for compliance purposes. The company had taken necessary steps to enable members to participate and vote electronically, and the voting results along with the Scrutinizer's Report will be placed on the company's website and intimated to BSE, NSE, and NSDL within two working days.
Entero Healthcare Solutions Ltd
Entero Healthcare Solutions Ltd reported Q1 FY27 earnings, with consolidated revenue growing 38.2% YoY to INR1,940 crores. EBITDA margin reached 5% for the quarter, and organic revenue growth was 17.8% on a reported basis and 19.6% on a like-for-like basis.
Entero Healthcare Solutions Ltd
Entero Healthcare Solutions Ltd has uploaded the audio recording of its earnings call for the quarter ended June 30, 2026, on its website.
Entero Healthcare Solutions Ltd
Entero Healthcare Solutions Ltd has published unaudited financial results for the quarter ended June 30, 2026, in newspapers as per SEBI regulations.
Entero Healthcare Solutions Ltd
Entero Healthcare Solutions Ltd has reported unaudited financial results for Q1FY27, with revenue growth of 40.0% YoY to INR 1,940 crore, EBITDA margins reaching 5.0%, and return ratios improving with ROCE nearly doubling y-o-y to 21.1% and ROE to 20.4%.
Entero Healthcare Solutions Ltd
Entero Healthcare Solutions Ltd has announced unaudited financial results for the quarter ended June 30, 2026, with a profit before exceptional items and tax of Rs. 46.05 crore, and a profit for the period of Rs. 34.57 crore.
Entero Healthcare Solutions Ltd
Entero Healthcare Solutions Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue from operations at Rs. 832.66 crore and profit before tax at Rs. 46.05 crore. The company has also reconstituted its Audit Committee, Nomination and Remuneration Committee, and Stakeholders Relationship Committee.
Entero Healthcare Solutions Ltd
Entero Healthcare Solutions Ltd revised its earnings call intimation for the unaudited financial results of the quarter ended June 30, 2026, with no changes to the schedule or details.
Entero Healthcare Solutions Ltd
Entero Healthcare Solutions Ltd has incorporated a step-down subsidiary, Qurovia Lifesciences Private Limited, with an authorized share capital of Rs. 1,50,00,000 and subscribed to 10,000 equity shares by R S M Pharma Private Limited.
Entero Healthcare Solutions Ltd
Entero Healthcare Solutions Ltd has submitted an updated Annual Report for the financial year 2025-26 due to an inadvertent error in the Consolidated Financial Statements. The report is available on the company's website and highlights the company's growth, expansion, and commitment to healthcare access across India.